We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Amivantamab

News List

Janssen files EGFR-targeting antibody amivantamab with EMA pharmatimes
January 05, 2021
Janssen, the pharmaceutical division of Johnson & Johnson, has submitted a marketing authorisation application to the European Medicines Agency (EMA) for approval of its epidermal growth factor receptor (EGFR)-targeting bispecific antibody amivantamab.
Janssen Submits BLA for Metastatic Lung Cancer Treatment americanpharmaceuticalreview
December 24, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab for the treatment of patients with metastatic ...
Janssen eyes US approval for EGFR-targeting NSCLC therapy pharmatimes
December 08, 2020
Janssen has submitted an application the US Food and Drug Administration (FDA) seeking approval for its non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations therapy amivantamab.
Janssen Announces Phase 1 Results for Amivantamab for Advanced NSCLC americanpharmaceuticalreview
May 21, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the Phase 1 CHRYSALIS study.